Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2020 | Comparing outcomes of 10-day decitabine with venetoclax vs. chemotherapy in AML based on fitness

Abhishek Maiti • 2 Jun 2020
EHA 2020
Acute Myeloid Leukemia Leukemia Decitabine Venetoclax

Abhishek Maiti, MD, University of Texas MD Anderson Cancer Center, Houston, TX, discusses a Phase II study comparing outcomes of older acute myeloid leukemia (AML) patients receiving DEC10-VEN vs. intense chemotherapy, overall and after stratification by ‘fitness’ for intense chemotherapy using a validated treatment-related mortality score. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Abhishek Maiti

2:16
Rationale for 10-day decitabine with venetoclax for high-risk AML
Abhishek Maiti • 1 Jun 2020
2:05
Venetoclax with decitabine for high-risk AML and MDS
Abhishek Maiti • 2 Jun 2020
6:21
Decitabine and venetoclax for AML
Abhishek Maiti • 1 Jun 2020

Related Videos

2:24
Manipulating the gut microbiome to improve outcomes of alloSCT for hematological malignancies
Florent Malard • 11 Apr 2024
2:05
Investigating mutation order in AML using single-cell sequencing
Ravindra Majeti • 8 Apr 2024
3:12
An epitope editing approach to enable the use of targeted immunotherapy in AML
Gabriele Casirati • 9 Apr 2024
0:59
Developing LSC-targeting agents in AML: progress and current therapeutic capacity
Ravindra Majeti • 8 Apr 2024
The content of VJHemOnc is intended for healthcare professionals